comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 18:34:26 - browse：9427

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

hotspot

WSS

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

The Harvard botanist who searched for psychedelics in the Amazon

6 phony surgeries that take placebo to the extreme

Gene therapy for Afghan refugees’ infant will be fully covered

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Community Health Systems hospitals under DOJ investigation

hotspot

comprehensive

explore

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What’s missing from the debate over nursing home staff minimums

The high cost of giving birth even with insurance

Ed Silverman on new gene therapies, biosimilars, coffee, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Medical records are filled with copy

Why Novartis is going to walk from its acquisition of MorphoSys

Affirmative action in medical school literally saved lives

New documents shed light on MD Anderson Cancer Institute feud

hotspot

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Readout LOUD: Venture capital, Gilead, and more M&A

340B reform proposal comes out of Senate working group

New documents shed light on MD Anderson Cancer Institute feud

A new nitrogen execution bill also undermines medical licensing

Top private equity targets in 2023: cardiology, clinical trials, lasers

entertainment

hotspot

knowledge

focus